Cue Biopharma, Inc. (CUE) Earnings History
Annual and quarterly earnings data from 2015 to 2025
Loading earnings history...
CUE EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CUE Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 87.3% | -96.7% | -96.9% |
| 2024 | 100.0% | -446.9% | -438.0% |
| 2023 | -593.9% | -949.9% | -924.1% |
| 2022 | 100.0% | -4275.1% | -4257.8% |
| 2021 | 111.9% | -292.6% | -295.6% |
Download Data
Export CUE earnings history in CSV or JSON format
Free sign-in required to download data
Cue Biopharma, Inc. (CUE) Earnings Overview
As of May 8, 2026, Cue Biopharma, Inc. (CUE) reported trailing twelve-month net income of -$27M, reflecting +61.1% year-over-year growth. The company earned $-7.22 per diluted share over the past four quarters, with a net profit margin of -96.9%.
Looking at the long-term picture, CUE's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2015.
Cue Biopharma, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$464M net income), AGIO (-$423M net income, -764.0% margin), KYMR (-$315M net income, -794.4% margin), CUE has comparable earnings metrics. Compare CUE vs IMVT →
CUE Earnings vs Peers
Earnings metrics vs comparable public companies
CUE Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$27M | +34.6% | -$27M | $-8.40 | -96.9% | -96.7% |
| 2024 | -$41M | +19.8% | -$42M | $-21.60 | -438.0% | -446.9% |
| 2023 | -$51M | +4.3% | -$52M | $-33.30 | -924.1% | -949.9% |
| 2022 | -$53M | -20.0% | -$53M | $-44.70 | -4257.8% | -4275.1% |
| 2021 | -$44M | +1.4% | -$44M | $-42.30 | -295.6% | -292.6% |
| 2020 | -$45M | -22.0% | -$45M | $-46.80 | -1419.8% | -1428.0% |
| 2019 | -$37M | +5.9% | -$37M | $-49.80 | -1061.2% | -1063.2% |
| 2018 | -$39M | -67.8% | -$39M | $-58.20 | -3411.5% | -3386.7% |
| 2017 | -$23M | -203.4% | -$23M | $-33.90 | - | - |
| 2016 | -$8M | -297.1% | -$8M | $-11.10 | - | - |
See CUE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CUE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CUE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCUE — Frequently Asked Questions
Quick answers to the most common questions about buying CUE stock.
Is CUE growing earnings?
CUE EPS is $-7.22, with earnings growth accelerating to +61.1%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-27M.
What are CUE's profit margins?
Cue Biopharma, Inc. net margin is -96.9%, with operating margin at -96.7%. Below-average margins reflect competitive or cost pressures.
How consistent are CUE's earnings?
CUE earnings data spans 2015-2025. The accelerating earnings trend is +61.1% YoY. Historical data enables comparison across business cycles.